Gain Therapeutics announces safe and well-tolerated Phase 1 results for experimental Parkinson's drug GT-02287.
Gain Therapeutics announces positive results from its Phase 1 trial of experimental drug GT-02287 for Parkinson's disease, showing it to be safe and well-tolerated. The company plans to start a trial in PD patients by Q4 2024 to demonstrate safety, patient tolerability, and proof of mechanism. GT-02287, a GCase-targeting small molecule, engages its peripheral target and is present in cerebrospinal fluid.
August 29, 2024
169 Articles